3 Hancock L, Mortensen NJ. How often do IBD patients require resection of their intestine[J]. Inflamm Bowel Dis, 2008, 14(Suppl 2): S68-S69.
[4]
4 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(4): 395-405.
[5]
5 Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort[J]. Gut, 2009, 58(4): 492-500.
[6]
6 Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis[J]. Gut, 2011, 60(1): 130-133.
[7]
7 Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up[J]. Aliment Pharmacol Ther, 2007, 26(5): 747-756.
[8]
8 J？rnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study[J]. Gastroenterology, 2005, 128(7): 1805-1811.
[9]
9 Eshuis EJ, Al Saady RL, Stokkers PC, et al. Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis[J]. J Crohns Colitis, 2013, 7(2): 142-149.
[10]
10 Yang Z, Wu Q, Wu K, et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis[J]. Aliment Pharmacol Ther, 2010, 31(4): 486-492.
[11]
11 Ehteshami-Afshar S, Nikfar S, Rezaie A, et al. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease[J]. Arch Med Sci, 2011, 7(6): 1000-1012.
[12]
12 Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis[J]. J Am Coll Surg, 2007, 204(5): 956-962.
[13]
13 Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis[J]. Dis Colon Rectum, 2007, 50(11): 1747-1753.
[14]
14 Mor IJ, Vogel JD, Da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy[J]. Dis Colon Rectum, 2008, 51(8): 1202-1207.
[15]
15 Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis[J]. Inflamm Bowel Dis, 2009, 15(7): 1062-1070.
[16]
16 Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications[J]. J Gastrointest Surg, 2008, 12(10): 1736-1737.
[17]
17 N？rg？rd BM, Nielsen J, Qvist N, et al. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis: a nationwide cohort study[J]. Aliment Pharmacol Ther, 2012, 35(11): 1301-1309.
[18]
18 Bregnbak D, Mortensen C, Bendtsen F. Infliximab and complications after colectomy in patients with ulcerative colitis[J]. J Crohns Colitis, 2012, 6(3): 281-286.
[19]
19 Gainsbury ML, Chu DI, Howard LA, et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch anal
20 Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study[J]. Aliment Pharmacol Ther, 2004, 19(7): 749-754.
[22]
21 Colombel JF, Loftus EJ, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy[J]. Am J Gastroenterol, 2004, 99(5): 878-883.
[23]
22 Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients[J]. J Gastrointest Surg, 2008, 12(10): 1738-1744.
[24]
23 Kasparek MS, Bruckmeier A, Beigel F, et al. Infliximab does not affect postoperative complication rates in Crohn’s patients undergoing abdominal surgery[J]. Inflamm Bowel Dis, 2012, 18(7): 1207-1213.
[25]
24 Nasir BS, Dozois EJ, Cima RR, et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease[J]. J Gastrointest Surg, 2010, 14(12): 1865-1866.
[26]
25 Rizzo G, Armuzzi A, Pugliese D,et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience[J]. Int J Colorectal Dis, 2011, 26(11): 1435-1444.
[27]
26 Simi M, Leardi S, Minervini S, et al. Early complications after surgery for Crohn’s disease[J]. Neth J Surg, 1990, 42(4): 105-109.
[28]
27 Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease[J]. Dis Colon Rectum, 2000, 43(8): 1141-1145.
[29]
28 Fasth S, Hellberg R, Hultén L, et al. Early complications after surgical treatment for Crohn’s disease with particular reference to factors affecting their development[J]. Acta Chir Scand, 1980, 146(7): 519-526.
[30]
29 Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry[J]. Clin Gastroenterol Hepatol, 2006, 4(5): 621-630.
31 Subramanian V, Saxena S, Kang JY, et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery[J]. Am J Gastroenterol, 2008, 103(9): 2373-2381.
